Otonomy and Ipsen in licensing agreement on gacyclidine for OTO-311 in tinnitus

6 November 2014

Ear disease and disorder specialist Otonomy (Nasdaq: OTIC) and French drugmaker Ipsen (Euronext: IPN) have entered into a licensing agreement which will enable Otonomy to use Ipsen’s gacyclidine data in the development and registration of OTO-311.

OTO-311 is Otonomy’s sustained-exposure formulation of gacyclidine, an N-Methyl-D-Aspartate receptor antagonist, which is being developed to treat tinnitus.

David Weber, president and chief executive of Otonomy, said: “We are pleased to complete this agreement with Ipsen which supports our plan to initiate OTO-311 clinical trials next year. Additionally, we believe that the clinical data set generated by Ipsen provides important insights into gacyclidine’s systemic profile that will inform our development of locally administered OTO-311 for the treatment of tinnitus.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK